- Strongest evidence: modest triglyceride reduction (25–30% with 2–4 g/day EPA+DHA) and reduced cardiovascular events in secondary prevention at prescription doses — FDA has approved icosapent ethyl (EPA-only, 4 g) after the REDUCE-IT trial.
- For primary prevention of heart disease in the general population, effects are modest at best — a large Cochrane review of 79 trials (112,059 people) found little to no cardiovascular mortality benefit at OTC supplement doses.
- Best forms by absorption: re-esterified triglyceride (rTG) > natural triglyceride > ethyl ester > phospholipid (krill); algal oil is a solid vegan option with EPA+DHA, unlike ALA-only flaxseed which converts poorly (Cochrane, EFSA).
- Weak evidence for depression as a standalone treatment (higher-EPA formulas 1–2 g/day showed some effect in RCTs but heterogeneity is high), dry eye, and cognitive decline; strong evidence against for macular degeneration prevention (AREDS2).
- Bleeding risk is real at high doses (>3 g/day) especially with anticoagulants — flag with your prescriber before combining with warfarin, DOACs, or antiplatelets.
- Evidence grade: Contested
Ingredient deep dive · Heart & Cardiovascular
Omega-3 fatty acids work best for lowering high triglycerides, but the evidence is mixed for preventing heart attacks or strokes with ordinary over-the-counter fish oil. EPA/DHA from fish, algal oil, or prescription products are the active long-chain forms; flaxseed ALA is essential but converts poorly to EPA/DHA, usually below 15% according to NIH ODS. People on anticoagulants, antiplatelets, with atrial fibrillation, fish allergy, liver disease, planned surgery, pregnancy, or high-dose supplement use should treat omega-3 as a medication-like ingredient and review it with a clinician.
Table of contents
- Evidence summary
- What omega-3 fatty acids are
- All forms and types
- EPA-only vs DHA-only vs EPA+DHA
- How omega-3 works
- What works and what does not
- Benefits by claim
- Risks and all side effects
- All interactions
- Who should avoid omega-3 supplements
- Dosage and how to take
- FAQ
- Sources & funding notes
Evidence summary
| Claim | Evidence | Source country | Funding / conflicts traced | Strength |
|---|---|---|---|---|
| Prescription-strength EPA/DHA lowers triglycerides | AHA advisory and NIH ODS summarize triglyceride lowering; Cochrane interview reports about 15% triglyceride reduction and FDA labels approve 4 g/day prescription products for severe hypertriglyceridemia. | USA / UK | AHA page: funding not disclosed on hub; NIH/NCCIH are US government sources; Cochrane says it is free from commercial sponsorship in its public statement. | Contested |
| Ordinary fish-oil supplements prevent heart attack or stroke | Cochrane found little or no effect of long-chain omega-3 on all-cause mortality, cardiovascular mortality, stroke, or cardiovascular events; VITAL found no significant reduction in the composite CVD endpoint but did find fewer myocardial infarctions in subgroup analyses. | UK / USA | Cochrane: nonprofit, commercial sponsorship excluded in public statement; VITAL: NIH-funded with study agents donated by Pharmavite and Pronova/BASF. | Mixed |
| High-dose purified EPA reduces events in selected high-risk patients | REDUCE-IT showed icosapent ethyl 4 g/day reduced the primary composite cardiovascular outcome from 22.0% to 17.2% in statin-treated high-risk patients. | International | REDUCE-IT was sponsored by Amarin; several authors had Amarin roles, stock, consulting, or research funding. | Moderate, conflicted |
| High-dose mixed EPA+DHA prevents cardiovascular events | STRENGTH found no significant reduction in major cardiovascular events with 4 g/day EPA+DHA carboxylic acids and was stopped for futility. | International, 22 countries | STRENGTH was funded by AstraZeneca and multiple authors reported AstraZeneca ties. | Moderate, negative |
| Depression symptoms improve | Meta-analyses show small benefits mainly for EPA-rich formulas in people with depression, but another independent meta-analysis found little or no preventive effect for depression/anxiety symptoms. | China/Canada, UK, Iran | One depression meta-analysis declared no conflicts; WHO meeting support was disclosed in the prevention meta-analysis; several sources did not disclose funding. | Mixed |
| Cognitive decline or dementia improves | Cochrane reviews found no meaningful benefit for treatment of dementia and no evidence that fish oil prevents cognitive decline in older people. | International / UK | Cochrane funding not disclosed on public summary; no material industry funding found in the public summary. | Doesn't, for current evidence |
| Dry eye improves | Cochrane found long-chain omega-3 produced little to no symptom reduction versus placebo, while newer meta-analyses report improvements in symptoms and tear tests. | Australia/USA/International, Taiwan, Italy | Cochrane review had NIH salary support and one review author was an author on included trials; newer meta-analyses often had no funding disclosed. | Mixed |
| Rheumatoid arthritis joint symptoms improve | A systematic review of 20 RCTs found improvements in several RA activity markers but noted low overall trial quality. | Greece | Funding and conflicts not disclosed in PubMed summary. | Weak to moderate |
| Pregnancy supplementation improves infant outcomes | Cochrane found reduced preterm birth and early preterm birth, while USDA systematic review rated neurodevelopmental evidence limited or inconsistent. | International / USA | Cochrane noted 11 included trials reported industry funding; USDA review was funded by USDA Food and Nutrition Service. | Mixed |
| Flaxseed/ALA replaces EPA+DHA | NIH ODS says ALA conversion to EPA and DHA is typically below 15%, so ALA is not a reliable direct substitute for EPA/DHA needs. | USA | NIH ODS government source; no commercial conflicts disclosed. | Doesn't as a substitute |
What omega-3 fatty acids are
Omega-3 fatty acids are polyunsaturated fats with a double bond three carbons from the methyl end of the molecule, and the main nutritionally relevant forms are alpha-linolenic acid (ALA), eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), and the less-discussed docosapentaenoic acid (DPA) (NIH ODS). ALA is an essential fatty acid found in plant foods such as flaxseed, chia, walnuts, soybean oil, and canola oil, while EPA and DHA are long-chain omega-3s found mainly in seafood, fish oil, cod liver oil, krill oil, and algal oil (NIH ODS).
The active distinction is simple: ALA is a precursor, EPA is more tied to triglycerides and inflammatory lipid mediators, DHA is a major structural fat in the brain and retina, and DPA sits between EPA and DHA but has far fewer direct human trials (NIH ODS, DPA review). NIH ODS reports that humans usually convert less than 15% of ALA into EPA and DHA, which is why flaxseed oil should not be marketed as equivalent to fish oil or algal EPA/DHA (NIH ODS).
Text version of this infographic
| Omega-3 type | Main sources | Role | Practical interpretation |
|---|---|---|---|
| ALA | Flaxseed, chia, walnuts, soybean oil, canola oil | Essential plant omega-3 precursor | Useful nutrient, but conversion to EPA/DHA is usually below 15% according to NIH ODS. |
| EPA | Fish oil, krill oil, cod liver oil, algal EPA products, prescription icosapent ethyl | Triglyceride lowering and inflammatory lipid mediators | Most relevant for triglyceride lowering and EPA-rich depression research according to the depression meta-analysis. |
| DHA | Fatty fish, fish oil, cod liver oil, algal DHA | Brain and retinal structure | Important biologically, but DHA-dominant formulas have weaker evidence for depression than EPA-rich formulas according to the depression meta-analysis. |
| DPA | Seafood and some omega-3 oils in smaller amounts | Intermediate between EPA and DHA; potential specialized pro-resolving mediators | Promising but under-studied; one review found only two pure DPA human studies at the time of publication (DPA review). |
All forms and grades
| Form | Source | Bioavailability | Best use | India cost signal | Verdict |
|---|---|---|---|---|---|
| Fish oil | Oily fish; usually EPA+DHA in ethyl ester, triglyceride, or re-esterified triglyceride forms | Good when taken with fat-containing meals; bioavailability differs by formulation but matched-dose studies show fish oil and krill oil can reach similar plasma EPA+DHA over weeks. | General EPA+DHA supplementation and prescription-strength triglyceride lowering when medically indicated. | — | Best value for non-vegetarians who need EPA+DHA. |
| Krill oil | Antarctic krill; EPA/DHA often in phospholipid form plus astaxanthin | Some small, mostly conflicted studies suggest higher short-term plasma incorporation, but a 4-week matched-dose trial found no significant plasma or red blood cell EPA+DHA difference versus fish oil. | People who tolerate krill better or prefer smaller softgels, not people trying to maximize EPA/DHA per rupee. | — | Premium but not clearly superior. |
| Algal oil | Microalgae; vegan DHA and sometimes EPA+DHA | A randomized trial found microalgal oil was non-inferior to fish oil for raising plasma phospholipid DHA and EPA when normalized for intake, but the trial was internally funded by dsm-firmenich. | Vegetarians, vegans, fish allergy, sustainability preference, pregnancy DHA under clinician guidance. | — | Best vegetarian EPA/DHA route. |
| Cod liver oil | Fish liver oil; EPA/DHA plus vitamins A and D | Provides omega-3, but its distinguishing feature is fat-soluble vitamins, not superior omega-3 evidence. | Only when vitamin A/D content is appropriate and total retinol exposure is monitored. | — | Use cautiously because excess vitamin A/D is the unique risk. |
| Flaxseed oil / ALA | Flaxseed oil capsules or food-grade flaxseed | ALA is absorbed, but conversion to EPA/DHA is limited; NIH ODS says conversion is usually below 15%. | Vegetarian ALA intake and dietary diversity, not correction of low EPA/DHA status. | — | Useful food, weak EPA/DHA substitute. |
| Prescription omega-3 | Regulated products such as omega-3-acid ethyl esters and icosapent ethyl | Standardized, studied at 4 g/day doses, and monitored like medication. | Severe hypertriglyceridemia and selected high-risk cardiovascular patients under medical supervision. | Availability and price vary by prescription brand and pharmacy; do not substitute OTC products for prescription therapy. | Clinical-use form for high triglycerides. |
Fish oil
Fish oil is the default EPA+DHA supplement form because it is widely available, comparatively inexpensive, and directly contains the long-chain omega-3s most studied in clinical trials (NIH ODS). Fish oil quality matters because labels can vary in EPA/DHA dose per capsule, and a “1000 mg fish oil” capsule often contains only about 300 mg combined EPA+DHA unless the label states otherwise; Indian retail listings commonly show 180 mg EPA plus 120 mg DHA per 1000 mg capsule (Nutrabay fish oil listing).
Krill oil
Krill oil’s phospholipid marketing is stronger than its independent clinical-outcome evidence, because available bioavailability trials are small and several have industry ties or incomplete funding disclosure (krill/fish oil bioavailability trial, krill acute bioavailability trial). If the goal is a measured EPA+DHA dose at low cost, krill oil usually loses to fish oil .).
Algal oil
Algal oil is the most logical choice for vegetarians and vegans because it supplies preformed DHA and, in some products, EPA without relying on ALA conversion (NIH ODS). A recent microalgal-versus-fish-oil trial found non-inferior plasma phospholipid DHA/EPA response, but it was funded internally by dsm-firmenich and several authors were employees or contractors, so the bioavailability conclusion is useful but commercially conflicted (microalgal oil bioavailability trial).
Cod liver oil
Cod liver oil is not simply “fish oil with extra benefits” because the extra vitamins A and D create a separate safety problem at repeated high intakes (NCCIH). NCCIH specifically warns that fish liver oils such as cod liver oil may contain vitamins A and D, which can be toxic in excessive amounts, so cod liver oil should not be stacked casually with multivitamins, vitamin D tablets, or retinol-containing products (NCCIH).
Flaxseed and ALA
Flaxseed is a valuable food, but flaxseed oil is not a one-to-one replacement for EPA/DHA because conversion from ALA to long-chain omega-3s is inefficient (NIH ODS). For Indian vegetarians with low seafood intake, algal DHA/EPA is the more direct supplement strategy than relying on flaxseed capsules alone (Indian human milk omega-3 review).
EPA/DHA versus DPA
EPA and DHA dominate clinical research, while DPA is biologically interesting but not ready for consumer-facing claims (DPA review). A DPA review described DPA as an “iceberg” omega-3 because it is often overlooked and noted that only two pure-DPA human studies and 11 animal studies had been conducted, which makes DPA an insufficient-evidence supplement target (DPA review).
Text version of this infographic
- Fish oil: direct EPA+DHA, usually best value for non-vegetarians, and widely Nutrabay fish oil listing).
- Krill oil: direct EPA+DHA, often higher cost, and not clearly superior at matched doses; small trials are often industry-linked or under-disclosed (fish oil versus krill trial).
- Algal oil: direct vegetarian DHA/EPA and the best route for vegans or vegetarians who want preformed long-chain omega-3 (microalgal oil bioavailability trial).
- Cod liver oil: direct EPA/DHA plus vitamins A and D, so the extra vitamins are a safety variable rather than a guaranteed advantage (NCCIH).
- Flaxseed oil: ALA-rich but not a reliable EPA/DHA substitute because conversion is usually below 15% (NIH ODS).
EPA-only vs DHA-only vs EPA+DHA
“Omega-3” is not one intervention. The three supplementation strategies — EPA alone, DHA alone, and combined EPA+DHA — have sharply different human-trial records, and the headline omega-3 trials of the last decade split almost perfectly along this line: the two positive cardiovascular-outcomes trials used EPA-only, while nearly every large EPA+DHA cardiovascular trial came back null. This section separates the three so the evidence is not blurred together. Funding matters here: the positive EPA-only trials are industry-funded, while the null EPA+DHA trials include the best independently funded studies in the field.
| Dimension | EPA-only | DHA-only | EPA+DHA combined |
|---|---|---|---|
| Best cardiovascular-events evidence | REDUCE-IT and JELIS — both positive, both industry-funded (REDUCE-IT; JELIS) | No dedicated hard-outcomes megatrial exists | STRENGTH, VITAL, ASCEND, OMEMI — all null on the primary composite endpoint (STRENGTH; VITAL; ASCEND; OMEMI) |
| Triglyceride lowering | ~18–21% at 3.8–4 g/day (Innes & Calder 2018) | ~13% at 2.7 g/day, slightly greater than EPA at matched dose | ~19% at 4 g/day in STRENGTH (STRENGTH) |
| LDL cholesterol | Minimal rise (~2%) | Notable rise (~7–8%), significantly greater than EPA | Intermediate, dose- and ratio-dependent |
| Depression (adjunctive) | Effective at EPA ≥60% of formulation (Sublette 2011 meta) | Not shown effective; may blunt EPA near a 1:1 ratio | Generally ineffective at typical ~1:1 (EPA <60%) ratios |
| Dry eye | No dedicated large trial | No dedicated large trial | Null in the largest independent RCT (DREAM); positive only in smaller heterogeneous meta-analyses (DREAM) |
| Atrial fibrillation risk | Elevated at high dose (REDUCE-IT 3.1% vs 2.1%); highest pooled AF risk of the three | Possibly lower, but no dedicated safety trial | Elevated at high dose regardless of ratio (STRENGTH 2.2% vs 1.3%) (AF dose meta) |
| Funding independence of key trials | Both positive trials industry-funded (Amarin, Mochida) | Sole positive cognition trial industry-funded (MIDAS); largest trials independently funded and null | Null findings span independent (VITAL, ASCEND, OMEMI) and industry (STRENGTH) funding |
| Overall evidence grade | Moderate (CV events); Moderate (depression) | Weak to Insufficient | Contested (CV events); Weak (dry eye, depression) |
EPA-only
EPA-only products deliver eicosapentaeno acid in near-total purity, usually as an ethyl ester. The best-studied form is icosapent ethyl (Vascepa in the US, Epadel in Japan), a prescription-grade EPA approved by the FDA as an adjunct to statins for elevated triglycerides and cardiovascular risk reduction (REDUCE-IT, NEJM 2019). Over-the-counter “high-EPA” fish oil concentrates exist but lack the ≥96% purity and trial backing of the prescription product.
Cardiovascular events — the strongest signal of any omega-3 formulation. In REDUCE-IT (n=8,179 statin-treated patients with triglycerides 135–499 mg/dL, icosapent ethyl 4 g/day vs mineral-oil placebo), the primary composite endpoint fell from 22.0% to 17.2% (HR 0.75, 95% CI 0.68–0.83, p<0.001), with cardiovascular death alone reduced from 5.2% to 4.3% (HR 0.80, p=0.03) (REDUCE-IT). JELIS (n=18,645 Japanese patients, EPA 1.8 g/day added to a statin) cut major coronary events from 3.5% to 2.8% — a 19% relative risk reduction (p=0.011) (JELIS, Lancet 2007). A 2021 meta-analysis of 38 RCTs (149,051 participants) found EPA monotherapy produced larger risk reductions than EPA+DHA across cardiovascular mortality (RR 0.82 vs 0.94), MACE (RR 0.78 vs 0.99), and non-fatal MI (RR 0.72 vs 0.92), with a significant EPA-vs-EPA+DHA interaction (p=0.000005 for MACE) (Khan et al. 2021, EClinicalMedicine).
Triglycerides. EPA lowers triglycerides roughly 18–21% at 3.8–4 g/day, though DHA lowers them slightly more at matched doses (Innes & Calder 2018). Depression. A meta-analysis of 28 RCTs found omega-3’s antidepressant effect concentrated in supplements with ≥60% EPA content (SMD 0.558, p=0.001), versus a null effect for EPA<60% formulations — and the authors found no evidence DHA alone is effective (Sublette et al. 2011, J Clin Psychiatry, NIMH-funded, no industry conflicts).
Where EPA-only wins and loses. It is the only omega-3 formulation with positive cardiovascular-outcomes trials, and it carries the strongest depression signal. It is inferior to DHA for raising HDL, lowering blood pressure and heart rate, and broad anti-inflammatory marker reduction in head-to-head trials (Innes & Calder 2018). Its safety signal for atrial fibrillation and bleeding at 4 g/day is the largest of the three forms.
Safety. REDUCE-IT reported atrial fibrillation/flutter hospitalization in 3.1% vs 2.1% placebo (p=0.004), and a pooled analysis found EPA monotherapy carries higher AF risk than EPA+DHA (RR 1.35) and higher bleeding risk (RR 1.49) (REDUCE-IT; Khan 2021). Bleeding with anticoagulants and antiplatelets requires monitoring.
Typical dose. Cardiovascular risk reduction: 4 g/day (REDUCE-IT) or 1.8 g/day (JELIS, added to statin). Triglycerides: 3.8–4 g/day. Depression adjunct: ~200–2,200 mg/day EPA, with EPA ≥60% of total omega-3.
DHA-only
DHA-only supplements deliver docosahexaenoic acid in isolation, most commonly as algal oil, the vegetarian/vegan source widely used in prenatal and infant-nutrition products because it avoids fish-derived contaminants. DHA-only ethyl esters and triglyceride forms are also sold for maternal/infant nutrition and eye-health products.
Cardiovascular risk factors (not hard events). No DHA-only cardiovascular outcomes megatrial exists. In head-to-head comparator trials, DHA at 2.7 g/day lowered triglycerides by 13% (vs EPA’s 12%), raised HDL by 8% (p<0.0001, where EPA showed no significant HDL change), lowered 24-hour ambulatory blood pressure by 5.8/3.3 mmHg and heart rate by up to 3.7 bpm, and produced broader inflammatory-marker reductions (IL-6, IL-18, CRP, TNF-α) than EPA at the same dose (Innes & Calder 2018).
Cognition and infant development — largely null in independent trials. The NIA-funded DHA Alzheimer’s study found no effect on cognitive decline (ADAS p=0.41) in mild-to-moderate Alzheimer’s (JAMA 2010). The NHMRC-funded DOMInO trial (n=2,399 pregnant women, DHA 800 mg/day) found no significant difference in child cognitive or language composite scores at 18 months — and girls exposed to DHA in utero had poorer mean language and adaptive behavior scores than controls (DOMInO, JAMA 2010). The one positive cognition trial, MIDAS, was funded by Martek Biosciences — the algal-DHA manufacturer — which materially limits its independence.
Depression. The Sublette meta-analysis found no evidence DHA alone is acutely effective, and flagged that DHA may blunt EPA’s antidepressant effect near a 1:1 ratio (Sublette 2011).
Where DHA-only wins and loses. Superior to EPA for raising HDL, improving blood pressure and heart rate, and broader inflammatory-marker reduction. Inferior to EPA for hard cardiovascular events (no DHA-only megatrial), depression, and cognition/infant neurodevelopment in the largest independent trials.
Safety. The clinically relevant caveat is LDL elevation: DHA raised LDL by ~7% (p<0.0001) in head-to-head trials versus ~2% for EPA, a significantly greater effect (Innes & Calder 2018) — relevant for anyone treating high cholesterol. DHA may carry a lower atrial-fibrillation risk than high-dose EPA, but this rests on a STRENGTH sub-analysis, not a dedicated safety trial.
Typical dose. Cardiometabolic risk-factor trials: 2.7–3.8 g/day. Cognition trials: 800–900 mg/day. Maternal/prenatal: 800 mg/day (DOMInO).
EPA+DHA combined
This is the most common and most-studied form: fish oil, cod liver oil, krill oil, and prescription products like omega-3-acid ethyl esters (Lovaza) and omega-3 carboxylic acids (Epanova). It contains both EPA and DHA in ratios that vary by product, typically near natural marine ratios (often close to 1:1).
Cardiovascular events — the largest, most consistently null body of evidence. In the contemporary statin era, every major EPA+DHA cardiovascular-outcomes trial has been null on its primary composite endpoint. STRENGTH (n=13,078, omega-3 carboxylic acid 4 g/day vs corn oil, AstraZeneca-funded) reported 12.0% vs 12.2% (HR 0.99, p=0.84) and was stopped for futility (STRENGTH, JAMA 2020). VITAL (n=25,871, omega-3 1 g/day, NIH-funded) was null on its primary composite (HR 0.92, p=0.24) despite a 28% MI reduction in subgroup analysis (VITAL, NEJM 2019). ASCEND (n=15,480 diabetics, ~1 g/day, MRC/BHF-funded) was null (rate ratio 0.97, p=0.55) (ASCEND). OMEMI (n=1,027 elderly post-MI, 1.8 g/day, independently funded) was null (HR 1.08, p=0.60) (OMEMI). A Cochrane systematic review concluded there is little or no effect of EPA+DHA on all-cause mortality, cardiovascular mortality, or cardiovascular events (Cochrane).
Triglycerides. EPA+DHA reliably lowers triglycerides in a dose-dependent fashion above 2 g/day; STRENGTH showed a 19% relative reduction versus −0.9% for corn oil (p<0.001) — even though the cardiovascular-outcome was null (STRENGTH). Depression. Standard (~1:1, EPA<60%) fish oil is generally ineffective per the Sublette meta-analysis; only high-EPA-ratio formulations work (Sublette 2011).
Dry eye. The largest independently funded trial is negative: DREAM (n=535, EPA 2,000mg + DHA 1,000mg/day vs olive oil, NIH-funded) found no significant difference in OSDI symptom score (−13.9 vs −12.5, p=0.21) or any sign-based outcome (DREAM, NEJM 2018). A more heterogeneous meta-analysis of 19 RCTs was positive, but the single best-designed independent trial is negative (dry-eye meta 2023).
Where EPA+DHA wins and loses. It has the widest evidence base (most trials, largest samples, longest follow-up). It is inferior to EPA-only for hard cardiovascular events and depression, and negative for dry eye in the best independent trial. Crucially, its null cardiovascular findings span both independent (VITAL, ASCEND, OMEMI) and industry (STRENGTH) funding — so the null result is comparatively well-supported by independent evidence.
Safety. STRENGTH found new-onset atrial fibrillation in 2.2% vs 1.3% (HR 1.69, p<0.001) despite the null efficacy result, and GI adverse events in 24.7% vs 14.7%. A dose-response meta-analysis found AF risk rises with dose regardless of EPA:DHA ratio (~12% relative increase at ≤1 g/day, ~50% at 1.8–4 g/day) (AF dose meta). Bleeding signals at these doses were smaller than in high-dose EPA-only REDUCE-IT.
Typical dose. Cardiovascular megatrials: 1–4 g/day (all null on primary composite). Primary prevention (VITAL, ASCEND): ~1 g/day. Dry eye (DREAM): 3,000 mg/day (null).
How omega-3 works
Omega-3s become part of cell membranes and are used to make signaling molecules involved in cardiovascular, pulmonary, immune, and endocrine function (NIH ODS). EPA and DHA can reduce hepatic triglyceride production, alter very-low-density lipoprotein metabolism, and compete with omega-6 fatty acids in pathways that produce inflammatory and platelet-active lipid mediators (NIH ODS, MedlinePlus).
What the body does with it
ALA can be elongated and desaturated into EPA and DHA, but the conversion is limited and competes with omega-6 fatty acid metabolism (NIH ODS). EPA, DPA, and DHA can also generate specialized lipid mediators involved in resolving inflammation, but mechanistic plausibility does not equal clinical proof for every inflammatory condition (DPA review).
Why form and delivery matter
Form matters because “omega-3” can mean ALA, EPA, DHA, DPA, fish oil, krill oil, cod liver oil, algal oil, or a prescription ethyl ester product, and those are not clinically interchangeable (NIH ODS). Delivery matters because high-dose prescription trials used 4 g/day standardized products, while many retail capsules deliver far less EPA/DHA per capsule and have not been tested for the same endpoints (FDA LOVAZA label, FDA VASCEPA label).
What works and what does not
| Claimed benefit | Verdict | Evidence grade | Key caveat |
|---|---|---|---|
| Lowering triglycerides | WORKS | Contested | Best evidence is for prescription-strength EPA/DHA or EPA at 4 g/day under medical supervision, not low-dose “wellness” capsules (AHA advisory hub, FDA LOVAZA label). |
| Preventing heart attack or stroke in the general population | MIXED | Moderate | Cochrane finds little or no broad protection, while VITAL found fewer MIs in some analyses but not a significant reduction in the primary composite CVD endpoint (Cochrane 2020 interview, VITAL update). |
| Reducing cardiovascular events in selected high-risk patients | MIXED | Moderate | Purified EPA in REDUCE-IT was positive, but mixed EPA+DHA in STRENGTH was negative, and both major trials had industry funding (ACC REDUCE-IT summary, JAMA STRENGTH trial). |
| Depression | MIXED | Moderate | EPA-rich formulas show small treatment signals in depression, but prevention of depression/anxiety symptoms is not supported (depression meta-analysis, BMJ prevention meta-analysis). |
| Anxiety | INSUFFICIENT EVIDENCE | Weak | A 2023 review found too few anxiety trials for reliable meta-analysis (anxiety/depression review). |
| Cognitive decline / dementia | DOESN'T | Strong negative | Cochrane found no meaningful cognitive benefit for treatment or prevention in older adults (Cochrane dementia treatment, Cochrane dementia prevention). |
| Dry eye | MIXED | Weak to moderate | Cochrane was cautious, while newer meta-analyses report benefits; trial heterogeneity and comparator issues prevent a clean verdict (Cochrane dry eye review, 2023 dry eye meta-analysis). |
| Joint pain / rheumatoid arthritis | MIXED | Weak to moderate | Some RA markers improve, but trial quality is low and omega-3 is not a substitute for disease-modifying therapy (RA meta-analysis). |
| Infant development | MIXED | Moderate | Pregnancy omega-3 reduces early preterm birth in Cochrane, but neurodevelopment outcomes remain limited and inconsistent (Cochrane pregnancy review, USDA neurodevelopment review). |
| Inflammation in general | INSUFFICIENT EVIDENCE | Weak | Mechanisms are real, but “reduces inflammation” is too broad unless tied to a specific disease endpoint (NIH ODS, DPA review). |
Text version of this infographic
| Claim | Verdict | Why |
|---|---|---|
| Triglycerides | WORKS | AHA, NIH ODS, and FDA labels support prescription omega-3 for high triglycerides (AHA advisory hub, FDA LOVAZA label). |
| Heart attack/stroke prevention | MIXED | Cochrane found little or no broad benefit, while specific high-risk EPA trials reported benefit and EPA+DHA trials did not (Cochrane, JAMA STRENGTH trial). |
| Depression | MIXED | EPA-rich formulas show small benefits in depression, but prevention of depression or anxiety symptoms is not supported (depression meta-analysis, BMJ prevention meta-analysis). |
| Dementia/cognition | DOESN'T | Cochrane reviews found no meaningful effect for dementia treatment or prevention (Cochrane dementia treatment). |
| Dry eye | MIXED | Cochrane was cautious and newer meta-analyses were more positive (Cochrane dry eye review, 2023 dry eye meta-analysis). |
| Rheumatoid arthritis joint pain | MIXED | RA markers improved in a meta-analysis, but study quality was low (RA meta-analysis). |
| ALA replacing EPA/DHA | DOESN'T | ALA conversion to EPA/DHA is usually below 15% (NIH ODS). |
Benefits by claim
Triglycerides and severe hypertriglyceridemia
Omega-3’s cleanest benefit is lowering triglycerides, especially at prescription doses used for severe hypertriglyceridemia (AHA advisory hub). The FDA label for LOVAZA states that omega-3-acid ethyl esters are indicated as an adjunct to diet to reduce triglycerides in adults with severe triglycerides of at least 500 mg/dL and gives a daily dose of 4 g/day (FDA LOVAZA label).
The practical caveat is that triglyceride lowering is not the same as proven prevention of pancreatitis or cardiovascular events for every product, because the LOVAZA label states the effect on pancreatitis risk and cardiovascular mortality/morbidity has not been determined (FDA LOVAZA label).
Heart attack and stroke prevention
For healthy adults or people buying standard fish oil without a specific lipid target, the evidence does not support a simple “fish oil prevents heart attacks” message (Cochrane 2018 statement). Cochrane’s updated public summary says 86 RCTs involving 162,796 participants found little or no effect of long-chain omega-3 on all-cause mortality, cardiovascular mortality, cardiovascular events, stroke, or arrhythmia, although coronary heart disease outcomes may improve slightly (Cochrane 2020 interview).
The high-risk prescription-EPA story is different but conflicted: REDUCE-IT reported fewer cardiovascular events with icosapent ethyl 4 g/day, while STRENGTH found no benefit with high-dose EPA+DHA carboxylic acids and showed more atrial fibrillation (ACC REDUCE-IT summary, JAMA STRENGTH trial). REDUCE-IT was sponsored by Amarin and had extensive author ties to Amarin, while STRENGTH was funded by AstraZeneca and had AstraZeneca author conflicts, so the best conclusion is not “industry studies are invalid” but “the benefit appears formulation-, population-, and comparator-specific” (REDUCE-IT ACS analysis, JAMA STRENGTH trial).
Depression and anxiety
Omega-3 is not an antidepressant replacement, but EPA-rich formulas may have a small adjunctive role in diagnosed depression (depression meta-analysis). A 26-trial meta-analysis found an overall small improvement in depressive symptoms and reported that EPA-pure or EPA-major formulations showed benefits, while DHA-major formulations did not show clinical benefits (depression meta-analysis).
For prevention of depression or anxiety symptoms, the evidence is weaker because a large systematic review found long-chain omega-3 probably has little or no effect on depression symptoms and anxiety symptoms (BMJ prevention meta-analysis). A 2023 adult review found EPA-enriched interventions reduced depression severity but found too little anxiety evidence for meta-analysis (anxiety/depression review).
Cognitive decline and dementia
Omega-3 does not have convincing clinical evidence for treating dementia or preventing cognitive decline in older adults (Cochrane dementia treatment). Cochrane found no significant benefit on cognitive function, daily activities, dementia severity, quality of life, or mental health after six months of treatment (Cochrane dementia treatment).
Dry eye
Dry eye is genuinely mixed because a Cochrane review found long-chain omega-3 versus placebo showed little to no reduction in dry eye symptoms, while newer meta-analyses reported improvements in symptoms and tear-film measures (Cochrane dry eye review, 2023 dry eye meta-analysis). The most honest patient-facing verdict is “may help some people, not reliably enough to replace standard dry-eye care” because outcome measures, doses, and comparators vary across trials (Cochrane dry eye review).
Joint pain and rheumatoid arthritis
Omega-3 may modestly improve rheumatoid arthritis disease activity markers, but it should not be framed as a disease-modifying therapy (RA meta-analysis). A systematic review of 20 RCTs involving 1,252 patients found improvements in eight RA-related markers and reduced leukotriene B4, but the overall trial quality was described as low in the evidence brief (RA meta-analysis).
Infant development and pregnancy outcomes
Pregnancy evidence is split between obstetric outcomes and child neurodevelopment outcomes (Cochrane pregnancy review, USDA neurodevelopment review). Cochrane found omega-3 addition during pregnancy reduced preterm birth from 13.4% to 11.9% and early preterm birth from 4.6% to 2.7%, but also increased prolonged gestation beyond 42 weeks from 1.6% to 2.6% (Cochrane pregnancy review).
A USDA-funded systematic review found cognitive-development evidence was limited because 5 of 8 pregnancy supplementation RCTs reported some improvements but all 8 also reported at least one non-significant result, and evidence for language, social-emotional, motor, and visual outcomes was insufficient or inconsistent (USDA neurodevelopment review).
Inflammation
Omega-3s can influence inflammatory lipid mediator pathways, but “reduces inflammation” is too vague to be a reliable supplement claim without naming the disease and outcome (NIH ODS). DPA, EPA, and DHA can produce different specialized pro-resolving mediators, but DPA human supplementation evidence remains too sparse for consumer claims (DPA review).
Risks and all side effects
| Side effect or risk | Frequency / dose relationship | Mechanism or reason | What to do |
|---|---|---|---|
| Fishy aftertaste, unpleasant taste, taste perversion | Common; LOVAZA label lists taste perversion as >3% and greater than placebo. | Oil reflux and flavor compounds. | Take with meals, choose enteric-coated or refrigerated capsules, or switch form if persistent (FDA LOVAZA label). |
| Burping / eructation | Common; LOVAZA label lists eructation >3% and greater than placebo. | Reflux of oil from stomach. | Take with food or split dose; stop if severe (FDA LOVAZA label). |
| Dyspepsia, heartburn, stomach discomfort, nausea, vomiting, diarrhea, constipation | Common to occasional; STRENGTH reported gastrointestinal adverse events in 24.7% with omega-3 carboxylic acids versus 14.7% with corn oil. | Fat load and GI irritation. | Lower dose, take with food, or discontinue if persistent (JAMA STRENGTH trial, MedlinePlus). |
| Bad breath, bad-smelling sweat, headache | Usually mild and commonly reported by NCCIH. | Volatile oil metabolites and nonspecific intolerance. | Switch brand/form or stop if bothersome (NCCIH). |
| Musculoskeletal pain, peripheral edema, constipation, gout, atrial fibrillation with icosapent ethyl | VASCEPA label lists these as common in the cardiovascular outcomes trial at incidence at least 3% and at least 1% more frequent than placebo. | Observed adverse-event pattern in outcomes trial. | Use prescription EPA only under clinician monitoring (FDA VASCEPA label). |
| Atrial fibrillation or flutter | Dose-related signal at high doses; REDUCE-IT reported AF/flutter 5.3% versus 3.9%, and STRENGTH reported new-onset AF 2.2% versus 1.3%. | Uncertain electrophysiologic effect; higher risk in people with prior AF/flutter. | Avoid self-directed high-dose omega-3 if you have AF/flutter; monitor closely if prescribed (ACC REDUCE-IT summary, JAMA STRENGTH trial). |
| Bleeding tendency / prolonged bleeding time | Mainly high-dose or combined antithrombotic context; FDA VASCEPA label says bleeding risk was greater with concomitant antithrombotics. | Reduced platelet aggregation and prolonged bleeding time. | Monitor with anticoagulants, antiplatelets, bleeding disorders, and surgery (FDA VASCEPA label, NIH ODS). |
| Fish or shellfish allergic reaction | Rare but potentially serious; prescription labels warn that risk is uncertain in fish/shellfish allergy. | Fish-derived oil or capsule contaminants may trigger allergy. | Use algal oil or medical guidance if fish/shellfish allergy exists (FDA VASCEPA label, MedlinePlus). |
| LDL cholesterol increase | Relevant to EPA+DHA prescription products; LOVAZA label says LDL may increase. | DHA-containing products may raise LDL in some hypertriglyceridemia patients. | Monitor LDL periodically when treating high triglycerides (FDA LOVAZA label). |
| Liver enzyme concerns in hepatic impairment | Not a routine issue for healthy users; LOVAZA label recommends ALT/AST monitoring in hepatic impairment. | Medication-level omega-3 processing and underlying liver disease. | Clinician monitoring if liver disease is present (FDA LOVAZA label). |
| Vitamin A or D excess from cod liver oil | Dose-related and stack-related; risk increases when combined with multivitamins or vitamin D/retinol products. | Cod liver oil contains fat-soluble vitamins that accumulate. | Check vitamin A/D amounts and avoid stacking unless prescribed (NCCIH). |
| High-dose immune suppression concern | The Institute of Medicine noted that 900 mg/day EPA plus 600 mg/day DHA or more for several weeks might reduce immune function, while EFSA and FDA assessments cited by NIH ODS found up to about 5 g/day EPA+DHA appears safe for bleeding and immune endpoints. | Suppression of inflammatory responses. | Avoid chronic high-dose self-supplementation, especially with immunosuppression or active infection risk (NIH ODS). |
All interactions
| Interacts with | Type | Severity | Mechanism | Action |
|---|---|---|---|---|
| Warfarin | Medication | Monitor | Omega-3 may prolong bleeding time and may theoretically raise INR, although a retrospective warfarin study found fish/krill oil did not significantly affect time in therapeutic range or bleeding. | Do not start, stop, or change high-dose omega-3 without INR/clinician monitoring (NIH ODS, warfarin retrospective study). |
| DOACs: apixaban, rivaroxaban, dabigatran, edoxaban | Medication | Monitor / caution | Additive bleeding risk is plausible because FDA labels warn about anticoagulants and antithrombotics. | Avoid high-dose self-supplementation; ask the prescriber before combining (FDA VASCEPA label). |
| Heparin, low-molecular-weight heparins, fondaparinux | Medication | Monitor / caution | Additive anticoagulant or bleeding effect. | Use only with clinical supervision in hospital or perioperative settings (FDA VASCEPA label). |
| Antiplatelets: aspirin, clopidogrel, prasugrel, ticagrelor | Medication | Monitor | FDA labels state omega-3 products may prolong bleeding time and bleeding incidence was greater in people receiving antithrombotics. | Monitor bruising, nosebleeds, GI bleeding signs, and perioperative plans (FDA VASCEPA label, FDA LOVAZA label). |
| NSAIDs: ibuprofen, naproxen, diclofenac, high-dose aspirin | Medication | Use caution | NSAIDs can increase GI bleeding risk, while omega-3 may prolong bleeding time. | Avoid combining high-dose omega-3 with frequent NSAID use unless a clinician approves (NIH ODS). |
| SSRIs/SNRIs: sertraline, fluoxetine, escitalopram, venlafaxine, duloxetine | Medication | Use caution | SSRIs/SNRIs can impair platelet serotonin handling; omega-3 may add mild antiplatelet effect. | Watch for bruising or bleeding, especially if aspirin/NSAIDs are also used; evidence is theoretical rather than omega-3-specific trial proof (NIH ODS). |
| Blood pressure medicines: ACE inhibitors, ARBs, beta blockers, calcium-channel blockers, diuretics | Medication | Monitor if symptomatic | Omega-3 can modestly affect cardiovascular physiology, and people with multiple cardiometabolic drugs may be more sensitive. | Monitor dizziness or low blood pressure if taking high doses; do not replace prescribed BP therapy (NIH ODS). |
| Diabetes medicines: insulin, sulfonylureas, metformin, GLP-1 drugs, SGLT2 inhibitors | Medication / condition | Monitor | NIH ODS cites EFSA safety assessment stating up to about 5 g/day EPA+DHA has not been shown to affect glucose homeostasis, but diabetes is a condition requiring medication review. | Monitor lipids and glucose as usual; do not use omega-3 as diabetes treatment (NIH ODS, MedlinePlus). |
| Statins, especially atorvastatin | Medication | Generally compatible | VASCEPA label reports 4 g/day did not significantly change atorvastatin exposure in a drug-interaction study. | Commonly combined in high-risk patients under medical care; monitor lipids and adverse effects (FDA VASCEPA label). |
| Omeprazole / PPIs | Medication | No meaningful interaction shown for icosapent ethyl | VASCEPA 4 g/day did not significantly change omeprazole exposure in a drug-interaction study. | No special action for typical use; separate if GI tolerance requires (FDA VASCEPA label). |
| Rosiglitazone | Medication | No meaningful interaction shown for icosapent ethyl | VASCEPA 4 g/day did not significantly change rosiglitazone exposure. | Follow diabetes prescriber guidance (FDA VASCEPA label). |
| Orlistat | Medication | Possible reduced absorption | Orlistat inhibits fat absorption, and an animal study found reduced incorporation of EPA and DHA in tissues. | Separate timing and discuss if relying on omega-3 status; human evidence is limited (orlistat EPA/DHA study). |
| Cyclosporine and transplant immunosuppression | Medication / condition | Specialist only | Older cyclosporine studies evaluated fish oil in transplant or vascular-toxicity settings, and high-dose omega-3 has immune-function theoretical concerns. | Do not self-supplement after transplant without the transplant team (cyclosporine renal transplant trial, NIH ODS). |
| Other bleeding-risk supplements: ginkgo, garlic, ginger, ginseng, high-dose vitamin E, nattokinase, turmeric/curcumin | Supplement | Avoid stacking high doses | Several supplements may affect hemostasis, and fish oil is included in reviews of supplements with anticoagulant activity. | Avoid multi-supplement bleeding stacks before surgery or while on blood thinners (dietary supplements and bleeding review, anticoagulant supplements review). |
| Vitamin A, vitamin D, retinoids, multivitamins | Supplement / medication | Cod liver oil caution | Cod liver oil can contain vitamins A and D, creating additive fat-soluble vitamin exposure. | Avoid cod liver oil stacks unless total vitamin A/D is calculated (NCCIH). |
| Omega-6-rich diet | Dietary interaction | Nutritional competition | Omega-6 and omega-3 pathways compete for desaturation enzymes. | Improve food pattern rather than simply adding capsules to a poor diet (NIH ODS). |
| Atrial fibrillation or flutter | Medical condition | Use caution / avoid high-dose self-use | Prescription labels and major trials show increased AF/flutter risk, especially with prior AF/flutter. | Discuss with cardiologist before any high-dose omega-3 (FDA VASCEPA label, JAMA STRENGTH trial). |
| Liver disease, thyroid disease, pancreatic disease | Medical condition | Medical supervision | MedlinePlus specifically tells patients to inform clinicians about liver, thyroid, pancreatic disease, diabetes, or atrial fibrillation before prescription omega-3 use. | Use clinician-guided dosing and monitoring (MedlinePlus). |
| Fish/shellfish allergy | Medical condition | Avoid fish-derived forms unless cleared | Fish-derived prescription products warn that allergic-reaction risk is uncertain in fish/shellfish allergy. | Prefer algal oil and consult an allergist/clinician (FDA VASCEPA label). |
| Surgery, dental extraction, childbirth bleeding risk | Clinical situation | Tell clinician | Bleeding-time concerns matter most when combined with procedures or anticoagulants. | Disclose omega-3 use before procedures; follow surgeon/obstetrician instructions (FDA LOVAZA label). |
Text version of this infographic
| Risk level | Medication, supplement, or condition | Why it matters |
|---|---|---|
| High caution | Warfarin, DOACs, heparins, aspirin, clopidogrel, prasugrel, ticagrelor | FDA labels warn that omega-3 products may prolong bleeding time and require monitoring with anticoagulants or antiplatelets (FDA VASCEPA label). |
| High caution | Atrial fibrillation or flutter | High-dose trials and prescription labels show increased AF/flutter risk (JAMA STRENGTH trial). |
| High caution | Surgery, dental extraction, bleeding disorders | Bleeding-time effects matter most around procedures and in people with baseline bleeding risk (FDA LOVAZA label). |
| Caution | NSAIDs, SSRIs, SNRIs, high-dose vitamin E, ginkgo, garlic, ginger, ginseng, turmeric, nattokinase | These may add bleeding risk, especially when stacked with omega-3 and antithrombotic drugs (dietary supplements and bleeding review). |
| Caution | Blood-pressure and diabetes medicines | Not usually a hard contraindication, but cardiometabolic patients should monitor and use clinician-guided dosing (MedlinePlus). |
| Usually compatible under care | Statins and omeprazole | VASCEPA interaction studies did not show significant exposure changes for atorvastatin or omeprazole (FDA VASCEPA label). |
| Avoid stacking | Cod liver oil plus vitamin A, vitamin D, retinoids, or multivitamins | Fish liver oils can contain vitamins A and D, which can be toxic in excess (NCCIH). |
Who should avoid omega-3 supplements
Avoid or seek medical approval before omega-3 supplementation if you take anticoagulants, antiplatelets, frequent NSAIDs, have a bleeding disorder, have planned surgery, have atrial fibrillation/flutter, have fish or shellfish allergy, have liver/pancreatic/thyroid disease, are pregnant or breastfeeding, or use transplant immunosuppression (MedlinePlus, FDA VASCEPA label). Avoid cod liver oil specifically if you already take vitamin A, retinoid medicines, high-dose vitamin D, or multivitamins unless a clinician has calculated total intake (NCCIH).
Dosage and how to take
| Goal | Evidence-matched form | Typical evidence dose | Practical guidance |
|---|---|---|---|
| General omega-3 nutrition | Food first: oily fish for non-vegetarians; algal DHA/EPA for vegetarians; flax/chia/walnuts for ALA | No single official EPA/DHA RDA is set in the NIH ODS fact sheet, but ALA adequate intakes are listed and seafood is emphasized as a source. | Do not confuse ALA with EPA/DHA; check total EPA+DHA on labels (NIH ODS). |
| High triglycerides | Prescription omega-3-acid ethyl esters or icosapent ethyl | 4 g/day in FDA labels. | Use only under medical supervision; monitor LDL, bleeding risk, and AF risk (FDA LOVAZA label, FDA VASCEPA label). |
| High-risk cardiovascular patients with elevated triglycerides | Icosapent ethyl, not generic fish oil | 4 g/day in REDUCE-IT and FDA label. | This is a prescription decision because REDUCE-IT was positive but industry-funded and AF/bleeding monitoring is needed (ACC REDUCE-IT summary, FDA VASCEPA label). |
| Depression adjunct | EPA-major formula | Meta-analyses suggest EPA-rich products, often around 1 g/day EPA range, have the strongest signal. | Use only as adjunctive care, not a replacement for therapy or prescribed antidepressants (depression meta-analysis, anxiety/depression review). |
| Pregnancy | Food-based low-mercury seafood or clinician-approved DHA/EPA, including algal DHA for vegetarians | Cochrane analyzed varied pregnancy regimens and found lower preterm birth but more prolonged gestation. | Pregnancy dosing should be clinician-guided; avoid cod liver oil unless vitamin A/D exposure is reviewed (Cochrane pregnancy review, NCCIH). |
| Dry eye or joint pain | EPA+DHA products | No universally reliable dose because trials vary. | Consider only as a time-limited adjunct if standard care is in place and bleeding/AF risks are low (Cochrane dry eye review, RA meta-analysis). |
Take omega-3 capsules with meals that contain fat because fat-containing meals generally improve tolerability and absorption for lipid-based supplements (NIH ODS). Split doses if reflux or burping occurs, and do not chew or crush prescription softgels unless the label specifically allows it (FDA LOVAZA label, FDA VASCEPA label).
Text version of this infographic
- General nutrition: use food first, and if supplementing, choose a product that states actual EPA+DHA rather than only “fish oil mg” (NIH ODS).
- High triglycerides: evidence-matched dosing is prescription-level 4 g/day with medical monitoring, not casual OTC dosing (FDA LOVAZA label).
- Depression adjunct: EPA-rich formulas show the strongest signal, but they are adjuncts rather than replacements for mental-health treatment (depression meta-analysis).
- Pregnancy: use clinician-guided DHA/EPA and avoid uncalculated cod liver oil because fish liver oils can contain vitamins A and D (NCCIH).
Related research
For deeper, evidence-graded context on the conditions omega-3 is most often used for, see Pure City Research's condition guides:
- Heart disease: prevention and management guide
- Type 2 diabetes: prevention and management guide
- Stress, anxiety & depression: prevention and management guide
Independent funding and conflict notes
| Source | Country | Funding source | Conflict status | How we used it |
|---|---|---|---|---|
| NIH ODS omega-3 fact sheet | USA | US government; no commercial funding disclosed on page. | Independent government source; no material conflict found. | Background, forms, ALA conversion, safety, interactions. |
| NCCIH omega-3 overview | USA | US government. | Independent government source; no material conflict found. | Consumer safety, side effects, cod liver oil caution. |
| Cochrane cardiovascular review summary | UK / international evidence | Cochrane public summary did not list study-specific funding; Cochrane states work is free from commercial sponsorship in its omega-3 press release. | Independent systematic-review body. | Primary weight for broad cardiovascular prevention. |
| VITAL update | USA | NIH-supported investigator-initiated trial; ClinicalTrials.gov notes study agents donated by Pharmavite and Pronova/BASF. | Probably independent with product-donation caveat. | Primary-prevention nuance and subgroup signal. |
| REDUCE-IT ACS analysis | France/USA/Canada; parent trial international | Amarin Pharma sponsored REDUCE-IT. | Conflicted; several authors had Amarin employment, stock, consulting, or research funding. | Used cautiously for prescription EPA in selected high-risk patients. |
| STRENGTH trial | International, 22 countries | AstraZeneca AB. | Conflicted; multiple author AstraZeneca ties. | Counterweight to REDUCE-IT and high-dose EPA+DHA safety. |
| Depression meta-analysis | China / Canada | Not disclosed in PubMed summary. | Authors declared no conflict of interest. | EPA-rich depression signal. |
| BMJ prevention meta-analysis | UK | WHO meeting attendance funding disclosed for some authors. | Mostly independent; no material commercial conflict found in summary. | Depression/anxiety prevention claim. |
| Cochrane dementia treatment review | International | Not disclosed on public summary. | Independent review body; funding incompletely stated on public page. | Cognition/dementia verdict. |
| Cochrane dry eye review | Australia/USA/international | NIH National Eye Institute salary support for authors SMN and KL. | One author was senior author on two included studies; independent verification used. | Dry-eye caution. |
| Cochrane pregnancy review | International | Review public summary notes 11 included trials reported industry funding. | Independent review with included-trial industry funding caveat. | Pregnancy outcomes. |
| Microalgal oil bioavailability trial | Switzerland | Internal dsm-firmenich funding. | Conflicted; multiple authors were employees or contractors. | Used only for bioavailability, not broad benefit claims. |
Which omega-3 form is best: fish oil, krill oil, algal oil, cod liver oil, or flaxseed?
Fish oil is usually best value for direct EPA/DHA, algal oil is best for vegetarians and vegans, cod liver oil needs vitamin A/D caution, krill oil is premium-priced without clear matched-dose superiority, and flaxseed oil supplies ALA rather than reliable EPA/DHA. NIH ODS says ALA conversion to EPA/DHA is usually below 15%, which is the key reason flaxseed is not equivalent to fish oil or algal DHA/EPA (NIH ODS, fish oil versus krill trial).
Can vegetarians get enough omega-3 from flaxseed alone?
Vegetarians can get ALA from flaxseed, chia, walnuts, and oils, but flaxseed alone is not a dependable source of EPA/DHA because conversion is inefficient. If the goal is direct DHA or EPA, algal oil is the more evidence-matched vegetarian option (NIH ODS, microalgal oil bioavailability trial).
Does omega-3 help depression or anxiety?
Omega-3 may modestly help depression symptoms when formulas are EPA-rich, but it does not have strong evidence for preventing depression or anxiety symptoms. A 26-trial meta-analysis found benefits mainly for EPA-pure or EPA-major formulations, while a prevention meta-analysis found long-chain omega-3 probably has little or no effect on depression or anxiety symptoms (depression meta-analysis, BMJ prevention meta-analysis).
Does omega-3 thin the blood?
Omega-3 can reduce platelet aggregation and prolong bleeding time, especially at high doses, but most research does not show major bleeding problems at typical doses. The FDA labels still advise monitoring when omega-3 products are used with anticoagulants or antiplatelets, and people on warfarin, DOACs, aspirin, or clopidogrel should not start high-dose omega-3 without medical advice (NIH ODS, FDA VASCEPA label).
Is cod liver oil better than fish oil?
Cod liver oil is not automatically better because it adds vitamins A and D, which can be useful only when needed and risky when stacked with other supplements. NCCIH warns that fish liver oils may contain vitamins A and D that can be toxic in excessive amounts (NCCIH).
How much omega-3 should I take daily?
The right dose depends on the goal: food-first intake for general nutrition, clinician-guided 4 g/day prescription omega-3 for severe high triglycerides, EPA-rich adjunct formulas only when treating depression under care, and pregnancy dosing only with obstetric guidance. FDA labels for LOVAZA and VASCEPA use 4 g/day for prescription indications, but that dose should not be copied with over-the-counter capsules without monitoring (FDA LOVAZA label, FDA VASCEPA label).
Frequently asked questions
Is fish oil actually good for your heart?
For triglyceride reduction: yes, clearly, at 2–4 g/day EPA+DHA (25–30% reduction). For preventing heart attacks in otherwise healthy adults: not really — a Cochrane review of 79 trials found little to no cardiovascular mortality benefit from OTC-dose supplements. Prescription-dose EPA (icosapent ethyl, 4 g/day) does reduce events in high-risk patients per REDUCE-IT (Cochrane omega-3 review, REDUCE-IT).
Fish oil vs krill vs algal — which is best?
By absorption: re-esterified triglyceride (rTG) forms and natural triglyceride forms absorb best. Ethyl ester (most cheap fish oil) is fine when taken with a fatty meal. Krill oil has phospholipid-bound omega-3 and slightly better absorption per gram of EPA/DHA but is much more expensive per mg. Algal oil is the best vegan choice — it contains actual EPA+DHA, unlike flaxseed's ALA which converts poorly in the body (NIH ODS omega-3).
Can omega-3 cause bleeding?
At typical OTC doses (up to 3 g/day) bleeding risk is minimal in most people. At higher doses, and especially combined with anticoagulants like warfarin, DOACs (apixaban, rivaroxaban), or antiplatelets, bleeding risk becomes clinically relevant — flag it with your prescriber before or after starting (NCCIH omega-3).
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.